[ DB00065 . Role in the treatment of psoriasis ] . Psoriasis is one of the immune-mediated inflammatory diseases ( IMIDs ) , in whose pathogenesis Th1-mediated immune responses are considered crucial . DB00065 is a chimeric monoclonal antibody directed against the Th1-cytokine P01375 that has already been approved for the therapy of psoriatic arthritis ( in combination with methotrexate ) . In clinical studies , infliximab has proved safe and effective in treating plaque-type psoriasis . In 80 % of treated patients , the Psoriasis Area and Severity Index ( PASI ) decreased after 10 weeks by > or =75 % . DB00065 is expected to be approved as second-line therapy in Germany this year for the treatment of psoriasis vulgaris .